N@N

Matthew Biegler Reiterated (ZNTL) at Buy and Held Target at $20 on, Sep 16th, 2024

Matthew Biegler of Oppenheimer, Reiterated "Zentalis Pharmaceuticals, Inc." (ZNTL) at Buy and Held Target at $20 on, Sep 16th, 2024.

Matthew has made no other calls on ZNTL in the last 4 months.

There are 6 other peers that have a rating on ZNTL. Out of the 6 peers that are also analyzing ZNTL, 4 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Robert Driscoll of "Wedbush" Upgraded from Sell to Hold and Held Target at $4 on, Monday, August 12th, 2024
• Eliana Merle of "UBS" Downgraded from Strong Buy to Hold and Decreased Target to $5 on, Thursday, June 20th, 2024
• Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Hold and Decreased Target to $8 on, Tuesday, June 18th, 2024
• Derek Archila of "Wells Fargo" Downgraded from Buy to Hold and Decreased Target to $9 on, Tuesday, June 18th, 2024

These are the ratings of the 2 analyists that currently disagree with Matthew

---

• Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $20 on, Monday, August 12th, 2024
• Bradley Canino of "Stifel" Maintained at Strong Buy with Decreased Target to $10 on, Tuesday, June 18th, 2024

Contributing Sources

---